 Galapagos rose nearly 3 in early Amsterdam trade as Phase 3 studies of drug its making with Gilead Sciences showed sustained efficacy and a consistent safety profile in treating moderately to severely active rheumatoid arthritis. The companies said they will be presenting the data on filgotinib at the European League Against Rheumatisms European E-Congress of Rheumatology 2020. 